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Introduction
• Changes in fat distribution has been 
observed in patients on highly active 
antiretroviral therapy.
• The frequently reported drugs that cause 
fat redistribution are stavudine and 
protease inhibitors.
• Stavudine also causes a high incidence of 
metabolic complications and peripheral 
neuropathy.
Background
• Stavudine therapy is mostly associated with 
lipoatrophy or loss of subcutaneous fat.
– Prominent in the extremities and in the face
• Less commonly stavudine and protease 
inhibitors can cause fat accumulation syndromes
– Abdominal obesity
– A buffalo hump
– Isolated breast enlargement.
Background
• HIV associated lipodystrophy is 
multifactorial and the leading hypothesis 
include:
– Host related factors such as diet and gene 
mutations.
– Viral factors such as cytokine synthesis or 
depletion of polyunsaturated fatty acids.
Background
• Pharmacological or drug induced
– Mitochondrial DNA-polymerase inhibition
– Lipolysis inhibition
– Adiponectin (involved in lipid 
metabolism)synthesis reduction
• Reduced levels of adiponectin has been 
reported in HIV infected patients especially 
those receiving stavudive.
Background
• Lipodystrophy is more common in women
• Other high risk factors  cited in literature 
include:
– Low CD4 counts
– Higher CDC/WHO stage
– Low body mass index
– High viral load
– Previous use of other ARVs
Background
• Pattern of distribution is different in men 
and women
– Men: more peripheral lipoatrophy
– Women: mixed lopoatrophy and 
lipohypertrophy.
Background.
• In AMPATH clinics some patients were 
noted to have wasting of the extremities 
and face.
• Changes mainly noted by patients, family 
members and the clinicians.
• To describe and estimate the frequency of 
lipodystrophy in our setting we conducted 
a survey on 200 patients on long term 
ARV and their care providers.
Research question
• What is the pattern and frequencies of fat 
redistribution in a population of HIV 
infected patients in western Kenya, who 
have received at least 6 months of 
antiretroviral therapy?
Objectives
• To estimate the frequency of fat 
redistribution as perceived by the patients 
on ARV therapy
• To estimate the frequency of fat 
redistribution in those same patients as 
perceived by the care providers.
Methods
• Cross sectional survey of patients on ARV 
therapy followed up in AMPATH clinics.
• Survey instrument used was modified from 
the one used by the Multicenter AIDS 
Cohort Study (MACS) in the USA.
• Consecutive patients were recruited as 
they presented to the clinic.
• Research assistant asked the set of 
questions to both the patient and provider.



Methods
• Inclusion criteria
– Age 18 years or more
– History of ARV treatment for at least 6 months
– Willingness to answer survey questions
• Exclusion criteria
– Lack of willingness to participate
– Previous participation in the study.
Results
• Overall 200 patients were interviewed
• 144(72%) were women (typical of our 
patient population)
• The median duration of antiretroviral 
therapy was 15 months (range 6-
61months)
• The median weight was 60kg ( range 38-
97)
Results
• Median CD4 was 265 (1-1026).
• All patients were on HAART (2 NRTIS 
+1NNRTI or PI).
• 55 ( 27.5%)  patients reported change in 
fat distribution over the last 3 months
• Clinicians reported that 41(20.5%) patients 
had evidence of fat wasting or 
accumulation.
Table 1: Patient demographics
Variable Total Male (%)
N=56(28.0%)
Female
N=144(72%)
P-value
Weight
Median(range) 60(38-97) 65(48-95) 59(38-97) 0.0016
CD4 count
Median(Range) 265(1-1026) 216.5(1-728) 280(40-1026) 0.0088
ARV duration in months
Median(Range)
15(6-61) 14.5(6-48) 15(6-61) 0.9826
ARV change
Yes
No
14(7.0%)
186(93.0%)
3(5.36%) 11(7.64%) 0.2197
ARVs
Stavudine
Lamivudine
Nevirapine
Efavirenz
Zidovudine
Lopinavir_r
181(90.5%)
191(95.5%)
157(78.5%)
33(16.5%)
15(7.5%)
5(2.5%)
52(92.86%)
54(96.43%)
42(75.00%)
11(19.64%)
4(7.14%)
2(3.57%)
129(89.58%)
137(95.14%)
115(79.86%)
22(15.28%)
11(7.64%)
3(2.08%)
Table 2a: Changes in fat distribution (patient perceptions)
Variable Frequency (%) Male (%)
N=56(28.0%)
Female
N=144(72%)
P-value
Noticed change over last 3 months
Yes
No
55(27.50%)
145(72.50%)
13(23.21%)
43(76.79%)
42(29.17%)
102(70.83%)
0.3973
Changes in fat distribution
Fat accumulation (Increase) 
Wasting (Decrease)
Accumulation +Wasting (Both)
No change
43(21.50%)
2(1.00%)
9(4.50%)
146(73.00%)
11(19.64%)
0(0.00%)
2(3.57%)
43(76.79%)
32(22.22%)
2(1.39%)
7(4.86%)
103(71.53%)
Action taken
Yes
No
47(23.50%)
153(76.50%)
16(28.57%)
40(71.43%)
31(21.53%)
113(78.47%)
0.2915
Change in clothing
Too loose
Too tight
No change
16(8.21%)
43(22.05%)
136(69.74%)
3(5.45%)
11(20.00%)
41(74.55%)
13(9.29%)
32(22.86%)
45(67.86%)
0.5753
Table 2b: Changes in fat distribution (clinician’s perception)
Variable Frequency (%) Male (%)
N=56(28.0%)
Female
N=144(72%)
P-value
Patient exhibit changes in fat 
distribution
Fat accumulation (Increase)
Wasting (Decrease)
Accumulation +Wasting (Both)
No change
29(14.50%)
7(3.50%)
5(2.50%)
159(79.5%)
9(16.07%)
0(0.00%)
0(0.00%)
47(83.93%)
20(13.89%)
7(4.86%)
5(3.47%)
112(77.78%)
Results
• None of the risk factors such as weight, 
gender, CD4, type of ARV or duration of 
therapy were significantly related to the 
development of lipodystrophy in both 
univariate and multivariate analysis.
Conclusions
• Subjective lipodystrophy by patient or 
clinician survey was not uncommon
• Since most of our patients gain weight 
after starting ARVs, this probably 
represents a minimal estimate of 
lipoatrophy.
• Objective measures of fat loss such as 
DEXA scans and CT scans may yield 
higher estimates.
Conclusions
• The pattern of fat redistribution may be 
different in our setting as compared to the 
USA or Europe due to:
– Predominance of  women among our cohort
– Prevalent malnutrition
– Heterosexual mode of HIV transmission
• More studies are needed to identify the 
factors that are associated with 
lipodystrophy in our setting.
